Home › Clinical Trials › Cancer Clinical Trial › Pancreas › A phase 3, randomized, double-blind, placebo-controlled, multicenter study of pegylated recombinant human hyaluronidase (PEGPH20) in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in subjects with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma

Print
A A A

A phase 3, randomized, double-blind, placebo-controlled, multicenter study of pegylated recombinant human hyaluronidase (PEGPH20) in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in subjects with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma

Protocol Number: UCI-15-94

NCT Number: NCT02715804

Condition/Disease: Cancer - Pancreas

Principal Investigator: Jason Zell

Status: Open

Treatment: Treatment

Drugs: PEGPH20, Placebo

Therapies: Chemotherapy multiple agents systemic

Phase: 3

Age Group: Adult

Scope: Local

Learn More:
For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.